These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 12497543)

  • 61. Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.
    Stratta RJ; Pietrangeli C; Baillie GM
    Pharmacotherapy; 2010 Feb; 30(2):144-57. PubMed ID: 20099989
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
    Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
    Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Treatment of cytomegalovirus disease].
    Santos Luna F; Carratalà J
    Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 6():65-9. PubMed ID: 22541927
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cytomegalovirus infection in organ transplant recipients.
    Hibberd PL; Snydman DR
    Infect Dis Clin North Am; 1995 Dec; 9(4):863-77. PubMed ID: 8747770
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CMV resistance: "more complicated than we thought".
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1996 May; 2(5):37-9. PubMed ID: 11363529
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Leflunomide for cytomegalovirus: bench to bedside.
    Chacko B; John GT
    Transpl Infect Dis; 2012 Apr; 14(2):111-20. PubMed ID: 22093814
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
    Verkaik NJ; Hoek RA; van Bergeijk H; van Hal PT; Schipper ME; Pas SD; Beersma MF; Boucher CA; Jedema I; Falkenburg F; Hoogsteden HC; van den Blink B; Murk JL
    Transpl Infect Dis; 2013 Dec; 15(6):E243-9. PubMed ID: 24298985
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sensitivity of cytomegalovirus to intravenous foscarnet treatment.
    Akesson-Johansson A; Lernestedt JO; Ringdén O; Lönnqvist B; Wahren B
    Bone Marrow Transplant; 1986 Dec; 1(2):215-20. PubMed ID: 2844334
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cytomegalovirus (CMV) resistance to antivirals.
    Drew WL; Paya CV; Emery V
    Am J Transplant; 2001 Nov; 1(4):307-12. PubMed ID: 12099372
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Late and atypical cytomegalovirus disease in solid-organ transplant recipients.
    Slifkin M; Tempesti P; Poutsiaka DD; Snydman DR
    Clin Infect Dis; 2001 Oct; 33(7):E62-8. PubMed ID: 11528587
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    McGavin JK; Goa KL
    Drugs; 2001; 61(8):1153-83. PubMed ID: 11465876
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk factors and clinical outcomes of cytomegalovirus disease occurring more than one year post solid organ transplantation.
    Blyth D; Lee I; Sims KD; Gasink LB; Barton TD; Van Deerlin VM; Pfeiffenberger P; Blumberg EA
    Transpl Infect Dis; 2012 Apr; 14(2):149-55. PubMed ID: 22260410
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cytomegalovirus in solid organ transplantation.
    Rubin RH
    Transpl Infect Dis; 2001; 3 Suppl 2():1-5. PubMed ID: 11926743
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.
    Timpone JG; Yimen M; Cox S; Teran R; Ajluni S; Goldstein D; Fishbein T; Kumar PN; Matsumoto C
    Transpl Infect Dis; 2016 Apr; 18(2):202-9. PubMed ID: 26853894
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cytomegalovirus drug resistance and clinical implications.
    Chou SW
    Transpl Infect Dis; 2001; 3 Suppl 2():20-4. PubMed ID: 11926745
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Resistance studies: when are they indicated?].
    Angeles Marcos M
    Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 6():24-7. PubMed ID: 22541918
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus immune globulin in liver and intestinal transplantation.
    Tzakis AG
    Transpl Infect Dis; 2001; 3 Suppl 2():35-9. PubMed ID: 11926748
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Viral prophylaxis in organ transplant patients.
    Slifkin M; Doron S; Snydman DR
    Drugs; 2004; 64(24):2763-92. PubMed ID: 15563248
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.
    Razonable RR; Humar A
    Clin Transplant; 2019 Sep; 33(9):e13512. PubMed ID: 30817026
    [TBL] [Abstract][Full Text] [Related]  

  • 80. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation.
    Kotton CN; Kumar D; Caliendo AM; Asberg A; Chou S; Snydman DR; Allen U; Humar A;
    Transplantation; 2010 Apr; 89(7):779-95. PubMed ID: 20224515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.